A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
What is the purpose of this trial?
Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Parts B and C), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.
- Trial withCelgene Corporation
- Start Date08/26/2020
- End Date07/25/2021
- Last Updated08/28/2020
- Study HIC#2000025979